Drug Profile


Alternative Names: CI 1000; PD 141955

Latest Information Update: 28 Jun 1999

Price : $50

At a glance

  • Originator Pfizer
  • Developer BioCryst Pharmaceuticals; Pfizer
  • Class
  • Mechanism of Action Purine nucleoside phosphorylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Transplant rejection

Most Recent Events

  • 28 Jun 1999 Discontinued-I for Transplant rejection in USA (Unknown route)
  • 22 Jan 1996 Phase-I clinical trials for Transplant rejection in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top